Beyer, J, Albers, P, Altena, R, Aparicio, J, et al. 2012, “Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer.” Annals of Oncology. Retrieved from http://dx.doi.org/10.1093/annonc/mds579Journal Server
Haak, LL, Fenner, M, Paglione, L, Pentz, E & Ratner, H 2012, “ORCID: a system to uniquely identify researchers.” Learned Publishing, vol. 25, no. 4, pp. 259-264. Retrieved from http://dx.doi.org/10.1087/20120404Journal Server
Seidel, C, Busch, J, Weikert, S, Steffens, S, et al. 2012, “Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.” European Journal of Cancer, vol. 48, no. 7, pp. 1023-1030. Retrieved from http://dx.doi.org/10.1016/j.ejca.2012.02.048Journal Server
Fenner, M 2012, “One-click science marketing.” Nature Materials, vol. 11, no. 4, pp. 261-263. Retrieved from http://dx.doi.org/10.1038/nmat3283Journal Server
Seidel, C, Fenner, M, Länger, F, Bantel, H, et al. 2012, “Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST).” BMC Cancer, vol. 12, no. 1, p. 186. Retrieved from http://dx.doi.org/10.1186/1471-2407-12-186Journal Server
Seidel, C, Fenner, M, Reuter, C, Merseburger, AS, et al. 2011, “Retrospective Analyses of Patient Characteristics Having Predictive Impact on Survival under Everolimus.” Onkologie, vol. 34, no. 3, pp. 111-114. Retrieved from http://dx.doi.org/10.1159/000324668Journal Server
Fenner, M 2011, “ORCID: Unique Identifiers for Authors and Contributors.” Information Standards Quarterly, vol. 23, no. 3, p. 10. Retrieved from http://dx.doi.org/10.3789/isqv23n3.2011.3Journal Server
Fenner, M, Gómez, CG & Thorisson, GA 2011, “Key Issue
Collective Action for the Open Researcher & Contributor ID (ORCID).” Serials: The Journal for the Serials Community, vol. 24, no. 3, pp. 277-279. Retrieved from http://dx.doi.org/10.1629/24277Journal Server
Oechsle, K, Honecker, F, Cheng, T, Mayer, F, et al. 2011, “Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study.” Annals of Oncology, vol. 22, no. 12, pp. 2654-2660. Retrieved from http://dx.doi.org/10.1093/annonc/mdr026Journal Server
Grünwald, V, Weikert, S, Seidel, C, Busch, J, et al. 2011, “Efficacy of Sunitinib Re-Exposure after Failure of an mTOR Inhibitor in Patients with Metastatic RCC.” Onkologie, vol. 34, no. 6, pp. 310-314. Retrieved from http://dx.doi.org/10.1159/000328575Journal Server
Grünwald, V, Seidel, C, Fenner, M, Ganser, A, et al. 2011, “Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies.” British Journal of Cancer, vol. 105, no. 11, pp. 1635-1639. Retrieved from http://dx.doi.org/10.1038/bjc.2011.389Journal Server
Seidel, C, Fenner, M, Merseburger, AS, Reuter, C, et al. 2011, “Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients.” World Journal of Urology, vol. 29, no. 3, pp. 355-360. Retrieved from http://dx.doi.org/10.1007/s00345-010-0642-3Journal Server
Reuter, CWM, Morgan, MA, Ivanyi, P, Fenner, M, et al. 2010, “Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer.” World Journal of Urology, vol. 28, no. 3, pp. 391-398. Retrieved from http://dx.doi.org/10.1007/s00345-010-0527-5Journal Server
Lehmann, U, Dobbelstein, C, Fenner, M, Römermann, D, et al. 2009, “Complete cytogenetic remission after decitabine treatment in a patient with secondary AML harbouring high p15 INK4b gene methylation and high global DNA methylation.” Annals of Hematology, vol. 88, no. 3, pp. 275-277. Retrieved from http://dx.doi.org/10.1007/s00277-008-0584-7Journal Server
Fenner, M 2008, “Blogs, Wikis und Podcasts im Unterricht.” Biologie in unserer Zeit, vol. 38, no. 5, pp. 284-286. Retrieved from http://dx.doi.org/10.1002/biuz.200890080Journal Server
Fenner, M 2008, “Duplication: stop favouring applicant with longest list.” Nature, vol. 452, no. 7183, pp. 29-29. Retrieved from http://dx.doi.org/10.1038/452029aJournal Server
Fenner, MH, Beutel, G & Grünwald, V 2008, “Targeted therapies for patients with germ cell tumors.” Expert Opinion on Investigational Drugs, vol. 17, no. 4, pp. 511-522. Retrieved from http://dx.doi.org/10.1517/13543784.17.4.511Journal Server
Fenner, MH & Ganser, A 2008, “Erythropoietin in cancer-related anemia.” Current Opinion in Oncology, vol. 20, no. 6, pp. 685-689. Retrieved from http://dx.doi.org/10.1097/CCO.0b013e3283136971Journal Server
Fenner, MH & Elstner, E 2005, “Peroxisome proliferator-activated receptor-γ ligands for the treatment of breast cancer.” Expert Opinion on Investigational Drugs, vol. 14, no. 6, pp. 557-568. Retrieved from http://dx.doi.org/10.1517/13543784.14.6.557Journal Server
Zang, C, Liu, H, Posch, MG, Waechter, M, et al. 2004, “Peroxisome proliferator-activated receptor γ ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia.” Leukemia Research, vol. 28, no. 4, pp. 387-397. Retrieved from http://dx.doi.org/10.1016/j.leukres.2003.07.005Journal Server
Liu, H, Zang, C, Fenner, MH, Possinger, K & Elstner, E 2003, “PPARγ Ligands and ATRA Inhibit the Invasion of Human Breast Cancer Cells in vitro.” Breast Cancer Research and Treatment, vol. 79, no. 1, pp. 63-74. Retrieved from http://dx.doi.org/10.1023/A:1023366117157Journal Server
Zang, C, Wächter, M, Liu, H, Posch, MG, et al. 2003, “Ligands for PPARγ and RAR Cause Induction of Growth Inhibition and Apoptosis in Human Glioblastomas.” Journal of Neuro-Oncology, vol. 65, no. 2, pp. 107-118. Retrieved from http://dx.doi.org/10.1023/B:NEON.0000003728.80052.a8Journal Server
Elstner, E, Williamson, EA, Zang, C, Fritz, J, et al. 2002, “Novel Therapeutic Approach: Ligands for PPARγ and Retinoid Receptors Induce Apoptosis in bcl-2-positive Human Breast Cancer Cells.” Breast Cancer Research and Treatment, vol. 74, no. 2, pp. 155-165. Retrieved from http://dx.doi.org/10.1023/A:1016114026769Journal Server
Fenner, MH & Possinger, K 2002, “Chemotherapy for Breast Cancer Brain Metastases.” Onkologie, vol. 25, no. 5, pp. 474-479. Retrieved from http://dx.doi.org/10.1159/000067443Journal Server
Sado, T, Fenner, MH, Tan, S-S, Tam, P, et al. 2000, “X Inactivation in the Mouse Embryo Deficient for Dnmt1: Distinct Effect of Hypomethylation on Imprinted and Random X Inactivation.” Developmental Biology, vol. 225, no. 2, pp. 294-303. Retrieved from http://dx.doi.org/10.1006/dbio.2000.9823Journal Server
Fenner, MH, Parrish, JE, Boyd, Y, Reed, V, et al. 1998, “MSG1(Melanocyte-Specific Gene 1): Mapping to Chromosome Xq13.1, Genomic Organization, and Promoter Analysis.” Genomics, vol. 51, no. 3, pp. 401-407. Retrieved from http://dx.doi.org/10.1006/geno.1998.5383Journal Server
Shioda, T, Fenner, MH & Isselbacher, KJ 1997, “MSG1 and its related protein MRG1 share a transcription activating domain.” Gene, vol. 204, no. 1-2, pp. 235-241. Retrieved from http://dx.doi.org/10.1016/S0378-1119(97)00551-9Journal Server
About
The aim of this webpage is to demonstrate a better showcase of publications claimed as part of ORCID profiles.
The underlying R code queries Sciencecard for a given ORCID and returns the DOI for each publication. It, then, requests the CSL representation and metadata provided by CrossCite.
Built with
Packages used: XML, RJSONIO, httr and Brew. Styled with Foundation.